abstract |
An anti-α4β7 antibody, and a mixture of at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, which may delay the degradation of the anti-α4β7 antibody or may represent any combination thereof. The present invention further provides safe dosing regimens of these antibody formulations that are easy to follow and result in a therapeutically effective amount of an anti-alpha 4 [beta] 7 antibody in vivo. |